M2 muscarinic receptor Inhibitors
1 drugsAbout M2 muscarinic receptor
The M2 muscarinic receptor is a G protein-coupled receptor primarily located in the heart and smooth muscle. It mediates the slowing of heart rate and plays a role in cholinergic neurotransmission. As a subtype of the muscarinic acetylcholine receptor family, it is involved in various physiological processes.
Currently, there is no genetic evidence directly linking the M2 muscarinic receptor to specific diseases. However, its role in cholinergic neurotransmission makes it a potential target for drug development. Modulating M2 receptor activity has therapeutic potential in several areas.
There is one FDA-approved drug, darifenacin, that targets muscarinic receptors, approved in 2017. It is a small molecule drug developed by Macleods Pharms Ltd. and is categorized within the 'Other' therapeutic area.
Top M2 muscarinic receptor Drugs
Macleods Pharms Ltd. is the only company with an approved drug targeting M2.
The low number of competitors suggests a potential opportunity, but also a high barrier to entry.
M2 muscarinic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M2 muscarinic receptor, using small molecule modality.
Explore opportunities for novel modalities like antibodies or biologics to differentiate from existing treatments.
M2 muscarinic receptor Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on M2 muscarinic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 1 | 1 | 0% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M2 muscarinic receptor Drug Approval Timeline (2017 - 2017)
The first and most recent drug approval was in 2017, with darifenacin.
The lack of recent approvals indicates a potentially saturated market or challenges in developing new M2-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on M2 muscarinic receptor. A trial counts if an approved drug acting on M2 muscarinic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.